NCT05025332 - An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 14, 2022

Primary Completion Date

February 27, 2024

Study Completion Date

May 3, 2024

Conditions

Pitt Hopkins Syndrome

Interventions

DRUG

NNZ-2591

NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.

Trial Locations (5)

University of Alabama at Birmingham, Birmingham

Rush University Medical Center, Chicago

UT Southwestern, Dallas

Children's Hospital Colorado, Aurora

University of California at San Francisco, San Francisco